
    
      This is a prospective randomized control trial. There are two groups, study group and control
      group. Patients of study group accepted vancomycin strategies decided by a serum trough
      concentration model, and patients of control group accepted vancomycin dosage decided by
      attending physician. The primary endpoint is the incidence of reaching the target serum
      trough concentration, the secondary endpoint are clinical efficiency, antibiotic use and side
      effects such as acute kidney injury, etc.
    
  